p53 mutation heterogeneity in cancer

作者: T. Soussi , G. Lozano

DOI: 10.1016/J.BBRC.2005.03.190

关键词: Cancer researchGene mutationMutantCancerMissense mutationGeneBiologyGenetic heterogeneityOncogeneMutationBiophysicsCell biologyBiochemistryMolecular biology

摘要: The p53 gene is inactivated in about 50% of human cancers and the protein an essential component cell response induced by genotoxic stresses such as those generated radiotherapy or chemotherapy. It therefore highly likely that these alterations are important tumor resistance to therapy. particular characteristics alterations, 80% which missense mutations leading functionally heterogeneous proteins, make a unique class suppressor genes. A considerable number mutant proteins probably have oncogenic activity per se actively participate transformation. fact apoptotic antiproliferative functions can be dissociated certain mutants also suggests another level complexity relationships between inactivation neoplasia.

参考文章(69)
S. Rowan, R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, K. H. Vousden, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. The EMBO Journal. ,vol. 15, pp. 827- 838 ,(1996) , 10.1002/J.1460-2075.1996.TB00418.X
M S Greenblatt, W P Bennett, M Hollstein, C C Harris, Mutations in the p53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis Cancer Research. ,vol. 54, pp. 4855- 4878 ,(1994)
P. W. Hinds, S. J. Baker, C. A. Finlay, A. J. Levine, R. S. Quartin, B. Vogelstein, E. R. Fearon, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes Cell Growth & Differentiation. ,vol. 1, pp. 571- 580 ,(1990)
Bert Vogelstein, David Lane, Arnold J. Levine, Surfing the p53 network Nature. ,vol. 408, pp. 307- 310 ,(2000) , 10.1038/35042675
K. W. Kinzler, ONCOGENESIS: Landscaping the Cancer Terrain Science. ,vol. 280, pp. 1036- 1037 ,(1998) , 10.1126/SCIENCE.280.5366.1036
J Pohl, N Goldfinger, A Radler-Pohl, V Rotter, V Schirrmacher, p53 increases experimental metastatic capacity of murine carcinoma cells. Molecular and Cellular Biology. ,vol. 8, pp. 2078- 2081 ,(1988) , 10.1128/MCB.8.5.2078
Ella Kim, Wolfgang Deppert, Transcriptional activities of mutant p53: When mutations are more than a loss Journal of Cellular Biochemistry. ,vol. 93, pp. 878- 886 ,(2004) , 10.1002/JCB.20271
Sandy Chang & Guillermina Lozano Geng Liu, John M Parant, Gene Lang, Patty Chau, Arturo Chavez-Reyes, Adel K El-Naggar, Asha Multani, None, Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genetics. ,vol. 36, pp. 63- 68 ,(2004) , 10.1038/NG1282
Daniele Bergamaschi, Milena Gasco, Louise Hiller, Alexandra Sullivan, Nelofer Syed, Giuseppe Trigiante, Isik Yulug, Marco Merlano, Gianmauro Numico, Alberto Comino, Marlene Attard, Olivier Reelfs, Barry Gusterson, Alexandra K Bell, Victoria Heath, Mahvash Tavassoli, Paul J Farrell, Paul Smith, Xin Lu, Tim Crook, p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. ,vol. 3, pp. 387- 402 ,(2003) , 10.1016/S1535-6108(03)00079-5